German Risk Level Cut; Variants Get Greek Letters: Virus Update Bloomberg 1 hr ago Bloomberg News
(Bloomberg) The World Health Organization announced a plan to name coronavirus variants using the Greek alphabet, aiming to make it easier for the general public to discuss them.
Germany cut its risk level to “high” from “very high” in a further sign that the pandemic is loosening its grip on Europe’s largest economy. Bank of America Corp. plans to bring all staff in Hong Kong and mainland China back to the office by the end of June, making it one of the first global lenders in the Asian financial hub to push for a full return.
For the first time, the U.K. reported zero daily deaths of people within 28 days of a positive coronavirus test. In the U.S., New York City’s positivity rate dropped over the Memorial Day weekend to its lowest point since the pandemic began.
Article content
(Bloomberg) For the first time, the U.K. reported zero daily deaths of people within 28 days of a positive coronavirus test. In the U.S., New York City’s positivity rate dropped over the Memorial Day weekend to its lowest point since the pandemic began.
Chilean President Sebastian Pinera said in his annual speech to Chile’s congress that the government will create a $2 billion fund to finance the fight against Covid. Moderna Inc. became the second drugmaker to seek full U.S. approval for its vaccine.
We apologize, but this video has failed to load.
Try refreshing your browser, or
Word Count: 2325
Companies, meanwhile, are finding varying ways to envision the post-Covid workplace. Bank of America Corp. wants all of its Hong Kong staff back at their desks by the end of June, while Deutsche Bank AG unveiled its hybrid model for remote work.
Elsewhere in Europe, Germany cut its risk level to “high” from “very high,” a sign the pandemic is loosening its grip on Europe’s largest economy. The World Health Organization announced a plan to name variants using the Greek alphabet, aiming to make it easier for the general public to discuss them. Moderna Inc. became the second drugmaker to seek full U.S. approval for its vaccine.